Reubi JC, Waser B
The peptide carries a fatty-acid chain that binds albumin and extends its half-life, which supports once-weekly subcutaneous administration in clinical trials
We verify your benefits, prepare necessary documentation, submit to insurers, and oversee the approval process, which means you don't have to handle bureaucratic hassles
Meanwhile, manufacturing capacity remains the binding constraint: Novo Nordisk and Lilly have committed $8B+ to expand supply, but that capital takes 35 years to convert into commercial output
Triple agonists with GLP1, GIP and glucagon Given the efficacy and benefits of the dual GLP-1/GIP RA tirzepatide and the dual GLP-1/glucagon RA, a triple agonist targeting all three receptors (GLP-1/GIP/glucagon) may result in superior WL and glycaemic control than dual agonists
Complementary strategies, such as modified nutrition and increased movement, enhance their effectiveness